{"id":60412,"date":"2024-02-28T06:47:45","date_gmt":"2024-02-28T06:47:45","guid":{"rendered":"https:\/\/medsname.com\/rasalect\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rasalect","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/rasalect\/","title":{"rendered":"Rasalect"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Hurtigt svar<\/h3>\n

Rasalect<\/strong> er en oral rasagiline<\/strong> (1 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> anvendt til behandling af Parkinsons sygdom<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Unlike selegiline, rasagiline is ikke<\/em> metabolised to amphetamine derivatives, so insomnia is much less of a problem. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Vigtigt:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of serotoninsyndrom<\/em>.<\/p>\n<\/div>\n

\nHvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n

What Is Rasalect?<\/h2>\n

Rasalect is an oral tablet containing rasagiline 1 mg<\/strong>. rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Azilect<\/strong>. Rasalect is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Rasagiline was developed as a second-generation MAO-B inhibitor specifically to avoid selegiline’s amphetamine metabolites. It has a clean active metabolite (aminoindan) which itself has neuroprotective properties in laboratory models. Rasagiline can be used as monotherapy in early Parkinson disease or as adjunct to levodopa for end-of-dose wearing-off.<\/p>\n

How Does Rasalect (rasagiline) Work?<\/h2>\n

Rasagiline irreversibly inactivates MAO-B in the brain, slowing the breakdown of dopamine. Like selegiline it is selective for MAO-B at therapeutic doses (1 mg\/day) but loses selectivity above 1.5–2 mg\/day. Its main metabolite, aminoindan, has its own potential neuroprotective activity in preclinical models — the basis for the ADAGIO disease-modification trial, which produced suggestive but not conclusive results.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
Funktion<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Typisk dosis<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\nNej<\/td>\nNej<\/td>\nJa<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
Indikation<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\nLav<\/td>\nLav<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Rasalect For?<\/h2>\n

Rasalect is appropriate for adults with Parkinson disease — either as monotherapy in early disease or as adjunct to levodopa in patients with motor fluctuations. Compared with selegiline, rasagiline is preferred when insomnia is a concern. Compared with safinamide, rasagiline is the better monotherapy option (safinamide is licensed only as adjunct).<\/p>\n

Dosering og administration<\/h2>\n

Den standard voksendosis er 1 mg \u00e9n gang dagligt<\/strong>, taken in the morning with or without food. There is no need for titration — full effect is reached within 1–2 weeks. Doses above 1 mg\/day are generally avoided as MAO-B selectivity is lost. In moderate hepatic impairment reduce to 0.5 mg\/day; in severe hepatic impairment avoid.<\/p>\n\n\n\n\n\n\n\n
Population<\/th>\nDosis<\/th>\n<\/tr>\n<\/thead>\n
Standard adult<\/td>\n1 mg once daily, morning<\/td>\n<\/tr>\n
Let leverfunktionsneds\u00e6ttelse<\/td>\n0.5 mg once daily<\/td>\n<\/tr>\n
Moderate-severe hepatic impairment<\/td>\nUndg\u00e5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally ikke<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

Almindelige bivirkninger<\/h2>\n

Headache (the most common — usually transient), arthralgia, dyspepsia, depression, postural hypotension, flu-like symptoms. Less common: hallucinations, insomnia (much less than selegiline), weight loss, falls. With levodopa: increased dyskinesia.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause serotoninsyndrom<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

L\u00e6gemiddel- og madinteraktioner<\/h2>\n